Strides Pharma Gains FDA Approval for Generic Fluoxetine 60mg Tablets
• Strides Pharma has received FDA approval for its generic Fluoxetine 60mg tablets, expanding its portfolio of this antidepressant drug.
• The approval allows Strides Pharma to offer a complete range of Fluoxetine products, including 10mg, 20mg, and 60mg tablets and capsules.
• Fluoxetine capsules and tablets have a combined market size of $130 million, offering a substantial commercial opportunity for Strides Pharma.
• Strides Pharma plans to launch all three strengths of Fluoxetine tablets in the near future, manufactured at its facility in Puducherry.
Strides Pharma Receives USFDA Approval for Generic Theophylline Extended-Release Tablets
• Strides Pharma's subsidiary secures USFDA approval for generic Theophylline extended-release tablets, used for chronic asthma and lung diseases.
• The approved drug, a generic version of Theo-Dur, addresses symptoms like wheezing and shortness of breath by relaxing bronchial muscles.
• Theophylline extended-release tablets, with a market size of $11.5 million, will be manufactured in Bangalore, enhancing Strides Pharma's portfolio.
• Strides Pharma's stock price surged following the announcement, reflecting investor confidence in the company's growth and market position.
© Copyright 2025. All Rights Reserved by MedPath